v3.26.1
Supplemental Income Statement Information
 6 Months Ended
Jun. 27, 2026
Supplemental Income Statement Elements [Abstract]  
Supplemental Income Statement Information Supplemental Income Statement Information
Disaggregated Revenues
Revenues by type are as follows:
Three months ended Six months ended
(In millions)June 27, 2026June 28, 2025June 27, 2026June 28, 2025
Revenues
Consumables
$5,073 $4,606 $9,794 $8,960 
Instruments
1,750 1,644 3,305 3,270 
Services
5,171 4,605 9,899 8,990 
Consolidated revenues$11,994 $10,855 $22,999 $21,219 
Revenues by geographic region based on customer location are as follows:
Three months endedSix months ended
(In millions)June 27, 2026June 28, 2025June 27, 2026June 28, 2025
Revenues
North America
$6,149 $5,722 $11,854 $11,235 
Europe
3,311 2,830 6,268 5,454 
Asia-Pacific
2,104 1,920 4,075 3,811 
Other regions
430 383 802 720 
Consolidated revenues$11,994 $10,855 $22,999 $21,219 
Each reportable segment earns revenues from consumables, instruments and services in North America, Europe, Asia-Pacific and other regions.
Revenues by business are as follows:
Three months endedSix months ended
(In millions)
June 27, 2026June 28, 2025June 27, 2026June 28, 2025
Revenues



Biosciences
$1,060 $1,075 $2,040 $2,068 
Genetic sciences
703 679 1,358 1,356 
BioProduction
941 745 1,834 1,416 
Other
112 — 219 — 
Life Sciences Solutions
2,815 2,499 5,450 4,840 
Chromatography and mass spectrometry
821 784 1,620 1,557 
Chemical analysis
318 292 603 578 
Electron microscopy
707 652 1,340 1,311 
Analytical Instruments
1,847 1,728 3,563 3,446 
Clinical diagnostics
290 276 561 539 
ImmunoDiagnostics
248 234 478 451 
Microbiology
166 159 326 311 
Transplant diagnostics
134 124 255 237 
Healthcare market channel
442 407 873 880 
Elimination of intrasegment revenues
(75)(65)(145)(137)
Specialty Diagnostics
1,205 1,134 2,346 2,282 
Laboratory products
608 601 1,176 1,183 
Research and safety market channel
2,036 1,883 3,863 3,610 
Pharma services
1,893 1,794 3,634 3,401 
Clinical research
2,396 1,955 4,524 3,894 
Elimination of intrasegment revenues and other
(240)(238)(468)(453)
Laboratory Products and Biopharma Services
6,693 5,995 12,729 11,635 
Elimination of intersegment revenues
(565)(501)(1,089)(983)
Consolidated revenues$11,994 $10,855 $22,999 $21,219 
Restructuring and Other Costs
In the first six months of 2026, restructuring and other costs primarily included continuing charges for headcount reductions and facility consolidations in an effort to streamline operations, impairment of long-lived assets, and, to a lesser extent, net charges for pre-acquisition litigation and other matters. In 2026, severance actions associated with facility consolidations and cost reduction measures affected approximately 1% of the company’s workforce.
As of July 31, 2026, the company has identified restructuring actions, primarily in the Laboratory Products and Biopharma Services segment, that it expects will result in additional charges of approximately $220 million, primarily in 2026, and expects to identify additional actions in future periods.
Restructuring and other costs are as follows:
Three months endedSix months ended
(In millions)June 27, 2026June 27, 2026
Life Sciences Solutions
$13 $23 
Analytical Instruments
17 21 
Specialty Diagnostics
3 3 
Laboratory Products and Biopharma Services
62 95 
Corporate
4 7 
$98 $147 
The following table summarizes the changes in the company’s accrued restructuring balance, which is included in other accrued expenses in the accompanying balance sheets. Other amounts reported as restructuring and other costs in the accompanying statements of income are summarized in the notes to the table.
(In millions)Total (a)
Balance at December 31, 2025$70 
Net restructuring charges incurred in 2026 (b)
72 
Payments
(65)
Currency translation and other(5)
Balance at June 27, 2026$72 
(a)The movements in the restructuring liability principally consist of severance and other costs associated with facility consolidations.
(b)Excludes $76 million of net charges, principally $60 million of charges for impairment of long-lived assets in the Laboratory Products and Biopharma Services segment.
The company expects to pay accrued restructuring costs primarily through 2026.
Earnings per Share
The company’s earnings per share are as follows:
Three months endedSix months ended
June 27,June 28,June 27,June 28,
(In millions except per share amounts)2026202520262025
Net income attributable to Thermo Fisher Scientific Inc.$1,736 $1,617 $3,387 $3,124 
Basic weighted average shares371 378 372 378 
Plus effect of: stock options and restricted stock units— — — 1 
Diluted weighted average shares371 378 372 378 
Basic earnings per share$4.68 $4.28 $9.11 $8.27 
Diluted earnings per share$4.68 $4.28 $9.10 $8.26 
Antidilutive stock options excluded from diluted weighted average shares
4 4 3 3